WebOct 4, 2024 · Adverse reactions that occurred with at least 5% greater frequency in the DVTd arm were infusion reactions, nausea, neutropenia, thrombocytopenia, … WebDec 22, 2024 · The NICE recommendation is based on data from the Phase 3 CASSIOPEIA study (Part 1) with a median follow-up of 18.8 months which compared DVTd to standard of care (bortezomib, thalidomide and dexamethasone (VTd) alone) as induction and consolidation therapy in newly diagnosed multiple myeloma patients eligible for ASCT. …
National Center for Biotechnology Information
WebFeb 25, 2024 · Active Comparator: Arm A: DVRd + ASCT+DVRd (Standard Therapy) Participants will receive daratumumab, bortezomib, lenalidomide and dexamethasone … Web• When compared with VTd, DVTd increased neutropenia, lymphopenia, and pneumonia. Infusion reactions to daratumumab (mostly mild) were reported in 35 percent. Daratumumab maintenance improved PFS among patients who underwent VTd induction (HR 0.32, 95% CI 0.23-0.46) but not among those who underwent DVTd induction (HR 1.02; 95% CI … how does the summer i turned pretty end
Daratumumab approved for multiple myeloma treatment
WebMay 20, 2024 · In the D-VTd arm, infusion-related reactions occurred in 35.4% of pts. Conclusions: D-VTd in induction prior to and consolidation after ASCT improved depth of response (sCR, ≥CR, and MRD... WebSep 26, 2024 · After a median follow-up of 18.8 months (range = 0-32.2), DVTd was associated with a 53% reduction in the risk of progression or death compared to … WebJun 3, 2024 · At the clinical cutoff (June 19, 2024), 461 patients (85%) in the D-VTd group and 437 patients (81%) in the VTd group completed all four induction and both consolidation cycles, and 489 patients (90%) and 484 patients (89%) had undergone autologous stem-cell transplantation ( figure 1 ). photogenx34